5-Alpha Reductase and DHT: How One Enzyme Shapes Testosterone's Effects

What Is 5-Alpha Reductase and Why Does It Matter?

5-alpha reductase is a membrane-bound NADPH-dependent enzyme that irreversibly reduces the 4,5 double-bond of testosterone to produce dihydrotestosterone. Three isoforms exist: SRD5A1 (skin, scalp), SRD5A2 (prostate, genital skin, liver), and SRD5A3 (brain, various tissues). Because DHT binds the androgen receptor with roughly three to five times the affinity of testosterone and dissociates far more slowly, tissues expressing high levels of 5-AR amplify the androgenic signal far beyond what circulating testosterone alone would produce. [1]

The clinical consequences are wide-ranging. In the scalp's dermal papilla cells, DHT miniaturizes hair follicles by shortening the anagen (growth) phase, the core mechanism behind androgenetic alopecia in genetically susceptible men. In the prostate, DHT is the primary driver of both benign prostatic hyperplasia (BPH) and a permissive environment for certain prostate cancer subtypes. At the same time, DHT in the brain and genitalia contributes meaningfully to erection quality and libido, which explains why men on 5-AR inhibitors sometimes report sexual side effects. [2]

During fetal development, SRD5A2 is indispensable: genetic SRD5A2 deficiency results in 46,XY individuals born with ambiguous genitalia who nonetheless virilize substantially at puberty when adrenal testosterone surges and alternative androgen pathways compensate. This natural experiment confirmed that DHT is required for external genital differentiation in utero but that testosterone itself can maintain many androgenic functions when 5-AR activity is absent. [3]

Free vs. Total Testosterone: Why the Distinction Matters Clinically

Total testosterone is the concentration of all testosterone molecules in the blood, whether bound to a protein or not. Free testosterone is the tiny unbound fraction, approximately 2-3% in men, that diffuses directly into cells and activates androgen receptors without requiring carrier-protein release. [4]

Clinicians who report only total testosterone may miss significant androgen deficiency. A man can carry a total testosterone of 550 ng/dL, which looks normal on paper, yet have free testosterone well below the 5th percentile if his sex hormone-binding globulin (SHBG) is elevated. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism explicitly states: "We suggest measuring free testosterone levels in patients in whom total testosterone concentrations are near the lower limit of the normal range and in whom an alteration in SHBG levels is suspected." [5] That single recommendation should reshape how every ordering physician reads a testosterone panel.

Bioavailable testosterone extends the concept one step further. It includes both free testosterone and the fraction loosely bound to albumin, since albumin's binding affinity for testosterone is approximately 1,000 times weaker than SHBG's, and testosterone can readily dissociate from albumin at the capillary level. Bioavailable testosterone therefore represents roughly 35-55% of total testosterone in a healthy adult male. When a patient's SHBG is elevated due to aging, liver disease, hyperthyroidism, or certain medications, the bioavailable fraction can drop even while total testosterone reads normal, producing real hypogonadal symptoms. [6]

Free testosterone can be measured directly by equilibrium dialysis, the gold-standard method, or estimated using validated formulas (Vermeulen equation) from total testosterone, SHBG, and albumin. Direct immunoassay-based free-T kits are less accurate and should not be used for clinical decisions. The Endocrine Society guideline recommends equilibrium dialysis or the Vermeulen calculation. [5]

SHBG Explained: The Protein That Controls Testosterone Availability

Sex hormone-binding globulin is a glycoprotein synthesized primarily in the liver. One SHBG molecule binds one sex steroid molecule with high affinity, and the binding is essentially irreversible on the timescale of tissue delivery. Because SHBG-bound testosterone cannot enter cells through the classical diffusion pathway, every unit increase in SHBG effectively lowers bioavailable androgen exposure. [7]

Several clinically important conditions raise SHBG and therefore reduce free testosterone. Aging alone increases SHBG by roughly 1-2% per year after age 40. Hyperthyroidism, liver cirrhosis, HIV infection, and use of anticonvulsants or estrogens all raise SHBG substantially. Obesity, hypothyroidism, nephrotic syndrome, and high insulin states lower SHBG, which can make total testosterone appear low while free T remains adequate. [7]

On TRT, exogenous testosterone suppresses LH and FSH (see HPG axis section below), but SHBG levels can also shift. Testosterone itself mildly suppresses SHBG production in the liver. Some men on TRT see SHBG fall, which raises free testosterone proportionally higher than total testosterone would suggest. Monitoring both values together gives a more complete picture of androgenic exposure. Men with persistently high SHBG on TRT who have inadequate symptom response might benefit from dose adjustments confirmed by free-T equilibrium dialysis rather than total-T alone. [5]

Reference ranges for SHBG in adult men are typically 10-57 nmol/L, though the Endocrine Society notes that the clinical significance of borderline values depends on concurrent free-testosterone measurement rather than SHBG in isolation.

The HPG Axis: How Testosterone Regulates Its Own Production

The hypothalamic-pituitary-gonadal (HPG) axis is the feedback loop that controls endogenous testosterone. The hypothalamus releases gonadotropin-releasing hormone (GnRH) in pulses every 60-120 minutes. GnRH reaches the anterior pituitary through the portal circulation and stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH acts on Leydig cells in the testes to produce testosterone; FSH acts on Sertoli cells to support spermatogenesis. [8]

Both testosterone and DHT feed back negatively on this axis. Testosterone aromatizes to estradiol in adipose tissue and elsewhere; estradiol is actually the dominant inhibitor of LH secretion at the pituitary. DHT contributes additional negative feedback at the hypothalamus. When exogenous testosterone is administered for TRT, circulating testosterone and estradiol rise, GnRH pulsatility diminishes, LH and FSH fall, and the testes reduce their own production. This is why most men on TRT show LH values near zero and experience testicular atrophy unless adjunct agents such as human chorionic gonadotropin (hCG) or clomiphene are co-prescribed. [9]

The degree of HPG suppression depends on dose, route, and frequency of TRT. Intramuscular testosterone cypionate 200 mg every two weeks produces pronounced peak-to-trough fluctuations in testosterone and LH, whereas weekly or twice-weekly dosing at 50-100 mg achieves more stable levels with comparable HPG suppression. Testosterone pellets and daily transdermal gels also suppress the axis fully, though the kinetics differ. Recovery of HPG axis function after TRT discontinuation typically requires 3-6 months but can take longer in men who have been on high-dose therapy for years. [10]

5-AR activity interacts with the HPG axis indirectly. DHT does not aromatize to estradiol, so tissues that convert testosterone to DHT rather than estradiol reduce the estrogenic feedback signal. Men with genetically lower aromatase activity may rely proportionally more on DHT for HPG suppression. Clinically, this interaction matters when a man takes an aromatase inhibitor on TRT: blocking estradiol production reduces pituitary feedback, LH rises, and the testes may partially recover function even on exogenous testosterone. [9]

How DHT Drives Hair Loss and Prostate Growth

DHT's role in androgenetic alopecia (AGA) is among the best-established relationships in endocrinology. In scalp follicles with the genetic susceptibility variant, DHT binds androgen receptors in dermal papilla cells, upregulates TGF-beta signaling, and progressively shortens the anagen phase from years to weeks. The follicle miniaturizes across successive cycles until it produces only vellus hair. [2]

Finasteride 1 mg (Propecia) selectively inhibits SRD5A2, reducing scalp DHT by approximately 60% and serum DHT by 70%. The 2-year Merck Phase III trial (N=1,553) showed finasteride 1 mg produced a mean increase of 107 hair counts per cm² versus a decrease of 37 in the placebo group (P<0.001). [11] Dutasteride 0.5 mg inhibits both SRD5A1 and SRD5A2, cutting serum DHT by over 90%, and shows superior efficacy for scalp hair retention in head-to-head data, though it carries a longer half-life of roughly five weeks versus finasteride's six to eight hours. [12]

Prostate growth driven by DHT is equally well documented. The Prostate Cancer Prevention Trial (PCPT, N=18,882) found that finasteride reduced the 7-year period prevalence of prostate cancer by 24.8% compared with placebo. [13] Men on TRT with elevated DHT who carry BPH symptoms or who have a rising PSA should be evaluated for 5-AR inhibitor co-therapy, though the decision requires shared decision-making given the sexual side effect profile discussed below.

The HealthRX clinical framework for monitoring DHT on TRT is to check a serum DHT level at baseline, at 6-8 weeks after dose stabilization, and annually thereafter. A serum DHT above 850 pg/mL on TRT warrants a clinical review of hair-loss symptoms, prostate symptoms (IPSS score), and PSA trend before any dose escalation. Men below age 40 with a strong family history of AGA may benefit from prophylactic finasteride 1 mg started concurrently with TRT initiation rather than after visible hair thinning has begun.

Sexual Function and DHT: The Side the Prescribing Literature Underplays

DHT is not simply a "bad actor" responsible for hair loss and prostate growth. Multiple receptor-dense tissues in the male reproductive system depend on DHT for normal function. Genital skin and penile tissue express high levels of SRD5A2, and DHT is a principal driver of nitric oxide synthase expression in penile smooth muscle cells. Several epidemiological studies link 5-AR inhibitor use to persistent sexual dysfunction lasting beyond drug discontinuation, a phenomenon reported under the label post-finasteride syndrome (PFS), though the mechanistic basis remains debated. [14]

The International Society for Sexual Medicine has not reached consensus on PFS causation, but published case series and a 2021 systematic review (Borgo et al., J Sex Med) found that approximately 1.4-6% of finasteride users report persistent erectile dysfunction, reduced libido, or ejaculatory dysfunction after stopping the drug. Men considering a 5-AR inhibitor for scalp hair preservation on TRT should discuss this risk explicitly before starting therapy. A trial period of 3-6 months with symptom tracking via validated instruments such as the International Index of Erectile Function (IIEF-5) provides objective data for the shared decision. [14]

Testosterone itself, independent of DHT conversion, supports libido through central androgen receptors in the hypothalamus and limbic system. So men on TRT who experience libido improvement may retain that benefit even if a 5-AR inhibitor is added. What DHT inhibition more selectively affects is erection quality mediated by penile tissue androgen signaling, not the central desire component, a distinction that matters when counseling patients.

Reading Your Testosterone Lab Panel: Total, Free, Bioavailable, and DHT

A complete androgen panel for a man considering or already on TRT should include total testosterone (morning, fasting preferred), free testosterone by equilibrium dialysis or Vermeulen calculation, SHBG, albumin (for Vermeulen calculation), estradiol (sensitive LC/MS assay), DHT, LH, FSH, PSA, and hematocrit. [5]

Total testosterone is measured in ng/dL in the United States. The Endocrine Society defines biochemical hypogonadism as a total testosterone consistently below 300 ng/dL on two morning measurements, confirmed by a second assay. [5] Free testosterone thresholds vary by assay method; the Vermeulen-calculated reference range for free T is approximately 50-210 pg/mL in men aged 20-49, with values below 65 pg/mL often associated with symptomatic androgen deficiency regardless of total testosterone. [6]

DHT is typically reported in pg/mL or ng/dL. Reference ranges differ between labs, but most peg normal male serum DHT at 112-955 pg/mL (approximately 30-260 ng/dL). Serum DHT on TRT can rise significantly above baseline because the higher circulating testosterone substrate feeds 5-AR enzymes in skin and prostate tissue. A serum DHT above the upper reference limit in a symptomatic man on TRT justifies a 5-AR inhibitor conversation, particularly if PSA has risen more than 1.4 ng/mL from baseline within any 12-month window, which the Endocrine Society flags as a threshold for urology referral. [5]

Estradiol (E2) on TRT deserves mention here because the testosterone-to-estradiol conversion via aromatase is the other major metabolic fate competing with 5-AR conversion. High E2 elevates SHBG further (via hepatic upregulation), compounding free-T suppression. The target E2 range on TRT at HealthRX is 20-40 pg/mL by LC/MS assay; values above 50 pg/mL warrant investigation of dose, body composition, and, where appropriate, a low-dose aromatase inhibitor trial such as anastrozole 0.25 mg twice weekly.

Optimizing TRT When 5-AR Conversion Is High

Some men on TRT convert an above-average proportion of testosterone to DHT due to upregulated 5-AR activity in skin and scalp. Clinically, this presents as rapid DHT elevation relative to testosterone dose, accelerated hair shedding, and worsening IPSS scores without total testosterone being excessively high. Several practical steps can address this.

Route selection changes DHT exposure meaningfully. Transdermal testosterone gels applied to the skin deliver testosterone directly to tissues rich in SRD5A1, producing DHT:T ratios approximately 30% higher than intramuscular injections at equivalent total-testosterone levels, according to a pharmacokinetic comparison published in the Journal of Clinical Endocrinology and Metabolism. Switching from a daily gel to weekly subcutaneous or intramuscular testosterone cypionate may reduce DHT for a given testosterone target. [15]

Dose reduction is the most straightforward intervention when DHT is supraphysiologic but total testosterone is near the top of range. Reducing from 100 mg/week to 70-80 mg/week of testosterone cypionate, then rechecking labs at 6 weeks, may bring DHT into range without sacrificing clinical benefit if free testosterone remains adequate.

If route change and dose reduction are insufficient, finasteride 1 mg daily specifically targets scalp and prostate DHT, while dutasteride 0.5 mg daily provides a more complete systemic DHT block. The choice depends on the relative priority of hair retention versus minimizing sexual side-effect risk, a conversation that should happen with documented shared decision-making. [12]

Finally, body-composition improvement consistently lowers SHBG in men with metabolic syndrome, which increases free testosterone and can allow a lower TRT dose to produce the same free-testosterone target, in turn reducing absolute DHT output from the lower testosterone substrate. A 10% reduction in body weight in men with BMI >30 has been associated with a mean 10-15% increase in total testosterone in observational data, a finding replicated in the ATLAS trial cohort. [16]

Common Questions About 5-Alpha Reductase and DHT